SAP-001
Refractory/Tophaceous Gout
Phase 2Active
Key Facts
About Shanton Pharma
Shanton Pharma is a private, clinical-stage biotech headquartered in Princeton, NJ, with a targeted focus on inflammatory and metabolic disorders, particularly gout. The company's lead asset, SAP-001, has achieved Fast Track designation and completed a successful End-of-Phase 2 meeting with the FDA, positioning it for a pivotal Phase 3 trial in refractory gout. Led by an experienced management team with deep industry expertise, Shanton is advancing a pipeline of small molecule therapies aimed at significant markets with high unmet need.
View full company profile